ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PQS Phoqus

8.00
0.00 (0.00%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Phoqus LSE:PQS London Ordinary Share GB00B0M4CD64 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 8.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Director/PDMR Shareholding

11/10/2007 8:01am

UK Regulatory


RNS Number:5221F
Phoqus Pharmaceuticals PLC
11 October 2007


                           Phoqus Pharmaceuticals plc

                           Directors' share dealings

West Malling, UK, 11 October 2007: Phoqus Pharmaceuticals plc (AIM: PQS)
("Phoqus" or the "Company"), the drug development company, announces that on 9
October 2007, Dr Peter Johnson, Chief Financial Officer of Phoqus, transferred
2,627 ordinary shares in the Company to exercising option-holders in his
capacity as nominee shareholder.

As previously announced, share options granted by the Company on 3 November 2005
were to be satisfied by the transfer of ordinary shares held by certain
institutional shareholders. In order to facilitate the transfer of shares to
option-holders, some of the institutional shareholders transferred shares to Dr
Peter Johnson, Chief Financial Officer, to hold the shares as their nominee
pending exercise of the share options by the option-holders, after which he
would transfer the relevant shares to the exercising option-holders.

Following the above transfer of 2,627 shares to exercising option-holders on 9
October, 279,519 shares are now held by Dr Johnson in his capacity as nominee,
representing 0.61 per cent of the issued share capital of the Company.  Dr
Johnson's beneficial ownership of Phoqus shares remains unchanged at 294,926
ordinary shares, or 0.64 per cent of the issued share capital of the Company.

Enquiries:

Phoqus Pharmaceuticals plc
Suzanne Smith, Company Secretary                             Tel:  01732 870227

Nomura Code Securities Limited
Phil Walker                                                  Tel:  020 7776 1200




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RDSEANEEFESXFFE

1 Year Phoqus Chart

1 Year Phoqus Chart

1 Month Phoqus Chart

1 Month Phoqus Chart